572 Biochemie
Refine
Has Fulltext
- yes (97)
Is part of the Bibliography
- yes (97)
Year of publication
Document Type
- Doctoral Thesis (52)
- Journal article (40)
- Master Thesis (2)
- Preprint (2)
- Book article / Book chapter (1)
Keywords
- Transkriptionsfaktor (5)
- DNS-Reparatur (4)
- Ubiquitin (4)
- Regulation (3)
- SMN (3)
- Saccharomyces cerevisiae (3)
- TFIIH (3)
- Thrombozyt (3)
- gene expression (3)
- mass spectrometry (3)
- platelet (3)
- ALS (2)
- Antibody (2)
- Antikörper (2)
- Cancer (2)
- Cytokine (2)
- DNA-Reparatur (2)
- Enzym (2)
- Expression (2)
- Fluoreszenz (2)
- G-Protein gekoppelte Rezeptoren (2)
- Genexpression (2)
- Immunreaktion (2)
- Interleukin 4 (2)
- Messenger-RNP (2)
- Messenger-RNS (2)
- Monoklonaler bispezifischer Antikörper (2)
- Nanopartikel (2)
- Röntgenkristallographie (2)
- Signaltransduktion (2)
- Transkription (2)
- USP (2)
- Ubiquitin-Protein-Ligase (2)
- Ubiquitinierung (2)
- Vaccinia-Virus (2)
- apoptosis (2)
- binding (2)
- enzyme (2)
- identification (2)
- immunoprecipitation (2)
- inflammation (2)
- magnetic resonance imaging (2)
- messenger RNA (2)
- mouse models (2)
- neuroblastoma (2)
- pICln (2)
- phosphorylation (2)
- protein (2)
- regulation (2)
- 26S proteasome (1)
- 5-HT1A (1)
- 5-HT2C (1)
- 7,8-dihydroxyflavone (7,8-DHF) (1)
- A2a-R receptor (1)
- AD5 mutation (1)
- AMP-activated protein kinase (AMPK) (1)
- Ackerschmalwand (1)
- Activation (1)
- Adhesion and degranulation promoting adapter protein (1)
- Affinity probe (1)
- Antigen CD40 (1)
- Antigen CD95 (1)
- Antigenrezeptor (1)
- Apoptose (1)
- Aptamer (1)
- Arrestine (1)
- Arzneimitteldesign (1)
- Assembly (1)
- AuNPs (1)
- Aurora-A (1)
- Automation (1)
- B-Zell-Lymphom (1)
- BCMA (1)
- BRAF mutations (1)
- BRCA1 (1)
- BRM (1)
- BRN-3A (1)
- BTB domain (1)
- Baff (1)
- Bakteriorhodopsin (1)
- Bauchspeicheldrüsenkrebs (1)
- Beige adipocytes (1)
- Bierhefe (1)
- Bioanorganische Chemie (1)
- Bioconjugate (1)
- Biologie (1)
- Biomarker (1)
- Bispecific T-cell engager (1)
- Bortezomib (1)
- Brahma (1)
- Breast-cancer (1)
- Bäckerhefe (1)
- C-MYC (1)
- C/EBP (1)
- CGG repeat (1)
- CLIP-seq (1)
- CPG Island (1)
- Cancer Metabolism (1)
- Candida albicans (1)
- Cdc48 (1)
- Chaetomium thermophilum (1)
- Chemotherapie (1)
- Chemotherapy (1)
- Chimeric Antigen Receptor (1)
- Chimärer Antigenrezeptor (1)
- Chinese family (1)
- Cholesterinstoffwechsel (1)
- Chromatin-remodeling complexes (1)
- Chromophor (1)
- Chromosomal Passenger Complex (1)
- Colorectal Cancer (1)
- Combination therapy (1)
- Cyclophosphamide (1)
- Cytoskeleton Chromosomal Passenger Complex Interaction GAR Domain (1)
- DHX30 (1)
- DNA (1)
- DNA Sekundärstruktur (1)
- DNA damage (1)
- DNA methylferase homolog (1)
- DNA repair (1)
- DNA secondary structure (1)
- DNA-binding proteins (1)
- DNS-Bindung (1)
- DNS-Bindungsproteine (1)
- DUB (1)
- Decapping (1)
- Deubiquitination (1)
- Deuteriumaustausch (1)
- Dickdarmkrebs (1)
- Differentiation (1)
- Dihydroisochinolinderivate (1)
- Dihydroisochinolinonderivate (1)
- Diphenylether (1)
- Disease (1)
- Distinct (1)
- Drosophila melanogaster (1)
- Drug delivery platform (1)
- Drug delivery system (DDS) (1)
- Dualstere Liganden (1)
- Dualsteric Ligands (1)
- E2 (1)
- Echinococcus (1)
- Excitatory/inhibitory imbalance (1)
- Exons (1)
- FMR1 (1)
- FMR2 (1)
- FMRP (1)
- FRET (1)
- FXR1 (1)
- FXR2 (1)
- Factor gene PRPF31 (1)
- FcgR (1)
- Fettsäurestoffwechsel (1)
- Fluorescence microscopy (1)
- Fluoreszenz-Resonanz-Energie-Transfer (1)
- Fluoreszenzmikroskopie (1)
- Fragiles-X-Syndrom (1)
- Fuchsbandwurm (1)
- G3BP (1)
- GAS2L3 (1)
- GLV-1H68 (1)
- Ganzkörperbestrahlung (1)
- Gen BRCA 1 (1)
- Gen notch (1)
- Gene Expression (1)
- Gene regulation (1)
- General Transcription Factor II H (1)
- Genes (1)
- Genexpressionsmaschinerie (1)
- Genome Instability (1)
- Genregulation (1)
- Gephyrin (1)
- Gold Nanoparticles (1)
- HUWE1 (1)
- Halobacterium halobium (1)
- Helikasen (1)
- Hemibodies (1)
- Hemibody (1)
- Hey Proteine (1)
- Hey proteins (1)
- Hitzeschockproteine (1)
- Hitzestress (1)
- Homebox gene (1)
- Hsc70 (1)
- Human Sodium/Iodide symporter (1)
- IN-VIVO (1)
- Ifn-gamma (1)
- In-Vivo (1)
- In-vivo (1)
- Induzierte pluripotente Stammzelle (1)
- Inhibition (1)
- Inhibitor (1)
- Inhibitorische Synapse (1)
- Inhibitory synapse (1)
- Insulinsekretion (1)
- Interferon <alpha-2a-> (1)
- KSR1 (1)
- Knochenmark (1)
- Knochenmarktransplantation (1)
- Kolorektales Karzinom (1)
- Konjugation (1)
- Kontrollierte Wirkstofffreisetzung (1)
- Krebs <Medizin> (1)
- Kristallographie (1)
- Kristallstruktur (1)
- LCK (1)
- Library Screening (1)
- Lipidumbau (1)
- Lung cancer (1)
- Lung squamous cancer cells (1)
- MAP-Kinase (1)
- MAPK (1)
- MDSCs (1)
- MIZ1 (1)
- MYCN (1)
- Macromolecular Assembly (1)
- Macromolecular Crystallography (1)
- Mechanismus (1)
- Megakaryocyte (1)
- Megakaryozyt (1)
- Metabolismus (1)
- Mevalonate Pathway (1)
- Modifikation (1)
- Molecular Chaperone (1)
- Molekulargenetik (1)
- MscS (1)
- Multidrug-Resistenz (1)
- Multiple Myeloma (1)
- Multiples Myelom (1)
- Muscarinrezeptor (1)
- Mutations (1)
- Myc (1)
- N-MYC (1)
- N-Myc (1)
- NA+/I-symporter (1)
- NEDMIAL (1)
- NFkB-Signalling (1)
- NO (1)
- NPY (1)
- Nanodiamant (1)
- Nanodiamond (1)
- Nanoparticles (1)
- Nekroptose (1)
- Nekrose (1)
- Neural precursor cells (1)
- Neuroblastom (1)
- Neuroblastoma (1)
- Neurodevelopmental diseases (1)
- Neuropeptide Hormone (1)
- Neuropeptidhormon (1)
- Notch Signalweg (1)
- Notch signalling (1)
- Nucleinsäuren (1)
- Nucleosidanaloga (1)
- Nucleoside (1)
- Nucleotide excision repair (1)
- Nude-mice (1)
- Nukleotid-Exzisions-Reparatur (1)
- Oligomerisation (1)
- OmoMYC (1)
- Oncolysis (1)
- Oncolytic vaccinia virus (1)
- Onkogen (1)
- Onkolyse (1)
- Opiatrezeptor (1)
- Opioide (1)
- P53 (1)
- P97 (1)
- PAR-CLIP (1)
- PDXP inhibitors (1)
- PGAS (1)
- PRPF31 (1)
- Partial Agonists (1)
- Partialagonismus (1)
- Particle analytics (1)
- Partikelanalytik (1)
- Pathway (1)
- Peptide (1)
- Peptidsynthese (1)
- Pharmakodynamik (1)
- Platelet (1)
- Pockenviren (1)
- Polo-like kinase 1 (1)
- Polyethylenglykole (1)
- Polyglycerol (1)
- Polymere (1)
- Polypeptidketten bindende Proteine (1)
- Poxviridae (1)
- Progenitor cells (1)
- Protease-sensitive release (1)
- Proteasom (1)
- Proteasome (1)
- Protein (1)
- Protein kinase D1 (PKD1) (1)
- Protein kinase D3 (PKD3) (1)
- Proteinbiosynthese (1)
- Protonenpumpe (1)
- Purpurmembran (1)
- Quadruplex-DNS (1)
- RIP3 (1)
- RNA (1)
- RNA binding protein (1)
- RNA binding proteins (1)
- RNA helicase (1)
- RNA interference (1)
- RNA metabolism (1)
- RNA splicing (1)
- RNA-Polymerase (1)
- RNA-polymerase-II (1)
- RNA-seq (1)
- RNS (1)
- RP11 (1)
- RecQ helicase (1)
- Rekonstitution (1)
- Reporter Cells (1)
- Reporter gene (1)
- Reporterzellen (1)
- Retinitis pigmentosa (RP) (1)
- Retinoic acid (1)
- Rezeptorpharmakologie (1)
- Rothmund-Thomson-Syndrome (1)
- SM proteins (1)
- SP117 mutation (1)
- SPION (1)
- Salmonella enterica (1)
- Schizophrenie (1)
- Schizosaccharomyces pombe (1)
- Screening (1)
- SdsR (1)
- Sekundärstruktur (1)
- Signalweg (1)
- Site-specific protein conjugation (1)
- Small nuclear RNP (1)
- Solid-phase peptide synthesis (1)
- Spleißosom (1)
- Squamous cell carcinoma (1)
- Ssl1 (1)
- Stammzelle (1)
- Structural Biology (1)
- Struktur (1)
- Strukturbiologie (1)
- Strumpellin (1)
- Subunit (1)
- T cells (1)
- T-Lymphozyt (1)
- T-cell engager (1)
- T-lymphocytes (1)
- TDRD3 (1)
- TFIIIC (1)
- TIAR (1)
- TNF (1)
- TOP mRNA (1)
- TOP3b (1)
- TRAF2 (1)
- TRI-SNRNP (1)
- TRNA(ASP) (1)
- TTF complex (1)
- TWEAK (1)
- Targeted drug delivery (1)
- Targeted therapies (1)
- Terminal Oligopyrimidine Tract (1)
- Tfb4 (1)
- Therapy (1)
- Thermotoleranz (1)
- Thiolase (1)
- Tissue Engineering (1)
- Transcription (1)
- Transcription factor (1)
- Transgenic zebrafish (1)
- Transkription <Genetik> (1)
- Translation <Genetik> (1)
- Translationsinitiation (1)
- Translationskontrolle (1)
- Transporter (1)
- Triglyceride (1)
- Trithorax (1)
- Tritiumaustausch (1)
- Tuberkulose (1)
- Tumor (1)
- Tumor models (1)
- Tumour (1)
- U snRNPs (1)
- UBE2S (1)
- USP28 (1)
- Ubiquitin-conjugating enzyme (1)
- Unique Selling Proposition (1)
- VACV (1)
- Vaccinia virus (1)
- Verweildauer (1)
- Virotherapie (1)
- Virotherapy (1)
- WASH complex (1)
- X-ray crystallography (1)
- YnaI (1)
- Zellteilung (1)
- Zellzyklus (1)
- Zink-Finger-Proteine (1)
- adaptive immunity (1)
- adsorption (1)
- alpha-IIb beta-3 (1)
- animal behavior (1)
- anti-sigma factor (1)
- antigen expression (1)
- antitumor immune response (1)
- antiviral immunity (1)
- aquired resistance (1)
- arginine (1)
- arterial elasticity (1)
- ascites (1)
- assembly chaperone (1)
- atherosclerosis (1)
- autoantibodies (1)
- autophagy (1)
- bacterial fatty-acid biosynthesis (1)
- biased agonism (1)
- binding mode (1)
- biochemistry (1)
- bioinformatics (1)
- bispecific (1)
- bispezifisch (1)
- blood (1)
- bone marrow (1)
- breast cancer (1)
- cancer microenvironment (1)
- cancer treatment (1)
- cations (1)
- cell carcinoma (1)
- cholesterol (1)
- circadian rhythms (1)
- coexpression (1)
- cohesin (1)
- colorectal cancer (1)
- coloteral cancer (1)
- comparative genomic hybridization (1)
- complexity (1)
- crystallography (1)
- cyanelle (1)
- cytokinin (1)
- cytokinin kinetin (1)
- cytoskeleton (1)
- deep sequencing (1)
- delipidation (1)
- density gradient centrifugation (1)
- deubiquitinase (1)
- diabetes (1)
- diacylglycerol (DAG) (1)
- differential centrifugation (1)
- diversity (1)
- domain (1)
- dominant-negative (1)
- down regulation (1)
- drospophila (1)
- dual targeting (1)
- ectopic release (1)
- electron cryomicroscopy (1)
- electron microscopy (1)
- embryos (1)
- endosomal trafficking (1)
- enoyl-ACP reductase (1)
- eukaryotic gene expression (1)
- evolutionary genetics (1)
- expression (1)
- extracellular domain (1)
- family (1)
- fluorescence (1)
- fluorescence imaging (1)
- fluorescence microscopy (1)
- fraxe mental retardation (1)
- genes (1)
- genome integrity (1)
- genome stability (1)
- genome-wide analysis (1)
- genomics (1)
- glycerol (1)
- glycine receptor (1)
- glycosylation (1)
- granulophagy (1)
- granulostasis (1)
- haploinsufficiency (1)
- histology (1)
- homeostasis (1)
- humanized tumor (1)
- hyperexpression techniques (1)
- iNOS (1)
- iPSCs (1)
- in vitro (1)
- in vivo imaging (1)
- in vivo toxicity (1)
- in-vitro (1)
- in-vivo (1)
- inhibition (1)
- inhibitor residence time (1)
- innate immune system (1)
- innate immunity (1)
- insulin (1)
- interaction networks (1)
- label-free quantification (1)
- limiting dilution cloning (1)
- lipid bilayer (1)
- lipid remodeling (1)
- liver (1)
- living cells (1)
- lymph nodes (1)
- mRNA metabolism (1)
- macrophages (1)
- males (1)
- malignant melanoma (1)
- mechanism (1)
- mechanosensing (1)
- mechanosensitive channels (1)
- melanoma (1)
- membrane potential (1)
- membrane proteins (1)
- membrane structures (1)
- metabolism (1)
- metastatic tumors (1)
- miR-181 (1)
- modulatory effects (1)
- molecular evolution (1)
- molecular mass (1)
- monoclonal stable cell (1)
- motor-neuron protein (1)
- mouse model (1)
- mutation (1)
- myeloablation (1)
- myeloma (1)
- ncuCyte\(^®\)S3 (1)
- neural crest factors (1)
- neurons (1)
- oligomerization (1)
- oncogene-induced senescence (1)
- oncolytic virus therapy (1)
- oncolytic viruses (1)
- organellar mapping (1)
- p34 (1)
- p44 (1)
- p97/VCP (1)
- pancreas (1)
- partial purification (1)
- peptide (1)
- permutation (1)
- peroxisome purification (1)
- phase transition (1)
- phenotypic screening (1)
- photooxidative stress (1)
- photosynthesis genes (1)
- plant hormones (1)
- plant-microbe interaction (1)
- poly(2-ethyl-2-oxazoline) (1)
- posttranscriptional gene regulation (1)
- prognostic biomarkers (1)
- prognostic relevance (1)
- promoter invasion (1)
- prostate cancer (1)
- protein argentine methyltranserase (1)
- protein domains (1)
- protein interactions (1)
- protein localization (1)
- protein subunit (1)
- protein synthesis (1)
- protein-lipid interactions (1)
- pulse wave velocity (1)
- pyridoxal phosphatase (PDXP) (1)
- quality control (1)
- quanititative proteomics (1)
- red blood cells (1)
- regulatory RNA (1)
- replication (1)
- rhodobacter sphaeroides (1)
- ribonuclease-P (1)
- ribosome (1)
- ribosome profiling (1)
- rod degeneration (1)
- sRNA (1)
- schizophrenia (1)
- separation (1)
- sequence (1)
- signaling (1)
- signalling (1)
- singlet oxygen stress (1)
- small RNA (1)
- snRNPs (1)
- spatial proteomics (1)
- spliceosomes (1)
- splicing defect (1)
- splicing factor (1)
- stem cells (1)
- structural mechanism (1)
- structure-based drug design (1)
- subcutaneous human tumors (1)
- systems biology (1)
- thermotolerance (1)
- thrombopoiesis (1)
- tissue microarray (1)
- toxins (1)
- transcription factors (1)
- transcription/replication conflicts (1)
- translation initiation (1)
- translational regulation (1)
- triple in situ hybridization (1)
- trispecific (1)
- tumors (1)
- tumourigenesis (1)
- tyrosine phosphorylation (1)
- ubiquitin chain formation (1)
- ubiquitin linkage specificity (1)
- ubiquitin recognition (1)
- ubiquitination (1)
- vitamin B6 (1)
- wall shear stress (1)
- zebrafish (1)
- zinc-finger (1)
- ΔNp63 (1)
- β cell (1)
- β3 adrenergic receptor (ADRB3) (1)
Institute
- Graduate School of Life Sciences (36)
- Lehrstuhl für Biochemie (32)
- Theodor-Boveri-Institut für Biowissenschaften (23)
- Rudolf-Virchow-Zentrum (14)
- Institut für Molekulare Infektionsbiologie (7)
- Institut für Experimentelle Biomedizin (4)
- Fakultät für Chemie und Pharmazie (3)
- Institut für Pharmazie und Lebensmittelchemie (3)
- Medizinische Klinik und Poliklinik II (3)
- Comprehensive Cancer Center Mainfranken (2)
Schriftenreihe
Sonstige beteiligte Institutionen
ResearcherID
The role of BRCA1 and DCP1A in the coordination of transcription and replication in neuroblastoma
(2021)
The deregulation of the MYC oncoprotein family plays a major role in tumorigenesis and tumour maintenance of many human tumours. Because of their structure and nuclear localisation, they are defined as undruggable targets which makes it difficult to find direct therapeutic approaches. An alternative approach for targeting MYC-driven tumours is the identification and targeting of partner proteins which score as essential in a synthetic lethality screen.
Neuroblastoma, an aggressive entity of MYCN-driven tumours coming along with a bad prognosis, are dependent on the tumour suppressor protein BRCA1 as synthetic lethal data showed. BRCA1 is recruited to promoter regions in a MYCN-dependent manner. The aim of this study was to characterise the role of BRCA1 in neuroblastoma with molecular biological methods.
BRCA1 prevents the accumulation of RNA Polymerase II (RNAPII) at the promoter region. Its absence results in the formation of DNA/RNA-hybrids, so called R-loops, and DNA damage. To prevent the accumulation of RNAPII, the cell uses DCP1A, a decapping factor known for its cytoplasmatic and nuclear role in mRNA decay. It is the priming factor in the removal of the protective 5’CAP of mRNA, which leads to degradation by exonucleases. BRCA1 is necessary for the chromatin recruitment of DCP1A and its proximity to RNAPII. Cells showed upon acute activation of MYCN a higher dependency on DCP1A. Its activity prevents the deregulation of transcription and leads to proper coordination of transcription and replication. The deregulation of transcription in the absence of DCP1A results in replication fork stalling and leads to activation of the Ataxia telangiectasia and Rad3 related (ATR) kinase. The result is a disturbed cell proliferation to the point of increased apoptosis. The activation of the ATR kinase pathway in the situation where DCP1A is knocked down and MYCN is activated, makes those cells more vulnerable for the treatment with ATR inhibitors.
In summary, the tumour suppressor protein BRCA1 and the decapping factor DCP1A, mainly known for its function in the cytoplasm, have a new nuclear role in a MYCN-dependent context. This study shows their essentiality in the coordination of transcription and replication which leads to an unrestrained growth of tumour cells if uncontrolled.
Atherosclerosis is an inflammatory disease of large and medium-sized arteries, characterized by the growth of atherosclerotic lesions (plaques). These plaques often develop at inner curvatures of arteries, branchpoints, and bifurcations, where the endothelial wall shear stress is low and oscillatory. In conjunction with other processes such as lipid deposition, biomechanical factors lead to local vascular inflammation and plaque growth. There is also evidence that low and oscillatory shear stress contribute to arterial remodeling, entailing a loss in arterial elasticity and, therefore, an increased pulse-wave velocity. Although altered shear stress profiles, elasticity and inflammation are closely intertwined and critical for plaque growth, preclinical and clinical investigations for atherosclerosis mostly focus on the investigation of one of these parameters only due to the experimental limitations. However, cardiovascular magnetic resonance imaging (MRI) has been demonstrated to be a potent tool which can be used to provide insights into a large range of biological parameters in one experimental session. It enables the evaluation of the dynamic process of atherosclerotic lesion formation without the need for harmful radiation. Flow-sensitive MRI provides the assessment of hemodynamic parameters such as wall shear stress and pulse wave velocity which may replace invasive and radiation-based techniques for imaging of the vascular
function and the characterization of early plaque development. In combination with inflammation imaging, the analyses and correlations of these parameters could not only significantly advance basic preclinical investigations of atherosclerotic lesion formation and progression, but also the diagnostic clinical evaluation for early identification of high-risk plaques, which are prone to rupture. In this review, we summarize the key applications of magnetic resonance imaging for the evaluation of plaque characteristics through flow sensitive and morphological measurements. The simultaneous measurements of functional and structural parameters will further preclinical research on atherosclerosis and has the potential to fundamentally improve the detection of inflammation and vulnerable plaques in patients.
Plant hormones are small regulatory molecules that exert pharmacological actions in mammalian cells such as anti-oxidative and pro-metabolic effects. Kinetin belongs to the group of plant hormones cytokinin and has been associated with modulatory functions in mammalian cells. The mammalian adenosine receptor (A2a-R) is known to modulate multiple physiological responses in animal cells. Here, we describe that kinetin binds to the adenosine receptor (A2a-R) through the Asn253 residue in an adenosine dependent manner. To harness the beneficial effects of kinetin for future human use, we assess its acute toxicity by analyzing different biochemical and histological markers in rats. Kinetin at a dose below 1 mg/kg had no adverse effects on the serum level of glucose or on the activity of serum alanine transaminase (ALT) or aspartate aminotransferase (AST) enzymes in the kinetin treated rats. Whereas, creatinine levels increased after a kinetin treatment at a dose of 0.5 mg/kg. Furthermore, 5 mg/kg treated kinetin rats showed normal renal corpuscles, but a mild degeneration was observed in the renal glomeruli and renal tubules, as well as few degenerated hepatocytes were also observed in the liver. Kinetin doses below 5 mg/kg did not show any localized toxicity in the liver and kidney tissues. In addition to unraveling the binding interaction between kinetin and A2a-R, our findings suggest safe dose limits for the future use of kinetin as a therapeutic and modulatory agent against various pathophysiological conditions.
Stable cell lines are widely used in laboratory research and pharmaceutical industry. They are mainly applied in recombinant protein and antibody productions, gene function studies, drug screens, toxicity assessments, and for cancer therapy investigation. There are two types of cell lines, polyclonal and monoclonal origin, that differ regarding their homogeneity and heterogeneity. Generating a high-quality stable cell line, which can grow continuously and carry a stable genetic modification without alteration is very important for most studies, because polyclonal cell lines of multicellular origin can be highly variable and unstable and lead to inconclusive experimental results. The most commonly used technologies of single cell originate monoclonal stable cell isolation in laboratory are fluorescence-activated cell sorting (FACS) sorting and limiting dilution cloning. Here, we describe a modified limiting dilution method of monoclonal stable cell line selection using the real-time fluorescence imaging system IncuCyte\(^®\)S3.
The ubiquitination of proteins serves as molecular signal to control an enormous number of physiological processes and its dysregulation is connected to human diseases like cancer. The versatility of this signal stems from the diverse ways by which ubiquitin can be attached to its targets. Thus, specificity and tight regulation of the ubiquitination are pivotal requirements of ubiquitin signaling. Ubiquitin-conjugating enzymes (E2s) act at the heart of the ubiquitination cascade, transferring ubiquitin from a ubiquitin-activating enzyme (E1) to a ubiquitin ligase (E3) or substrate. When cooperating with a RING-type E3, ubiquitin-conjugating enzymes can determine linkage specificity in ubiquitin chain formation. Our understanding of the regulation of E2 activities is still limited at a structural level.
The work described here identifies two regulation mechanisms in UBE2S, a cognate E2 of the human RING-type E3 anaphase-promoting complex/cyclosome (APC/C). UBE2S elongates ubiquitin chains on APC/C substrates in a Lys11 linkage-specific manner, thereby targeting these substrates for degradation and driving mitotic progression. In addition, UBE2S was found to have a role in DNA repair by enhancing non-homologous end-joining (NHEJ) and causing transcriptional arrest at DNA damage sites in homologous recombination (HR). Furthermore, UBE2S overexpression is a characteristic feature of many cancer types and is connected to poor prognosis and diminished response to therapy.
The first regulatory mechanism uncovered in this thesis involves the intramolecular auto-ubiquitination of a particular lysine residue (Lys+5) close to the active site cysteine, presumably through conformational flexibility of the active site region. The Lys+5-linked ubiquitin molecule adopts a donor-like, ‘closed’ orientation towards UBE2S, thereby conferring auto-inhibition. Notably, Lys+5 is a major physiological ubiquitination site in ~25% of the human E2 enzymes, thus providing regulatory opportunities beyond UBE2S. Besides the active, monomeric state and the auto-inhibited state caused by auto-ubiquitination, I discovered that UBE2S can adopt a dimeric state. The latter also provides an auto-inhibited state, in which ubiquitin transfer is blocked via the obstruction of donor binding. UBE2S dimerization is promoted by its unique C-terminal extension, suppresses auto-ubiquitination and thereby the proteasomal degradation of UBE2S.
Taken together, the data provided in this thesis illustrate the intricate ways by which UBE2S activity is fine-tuned and the notion that structurally diverse mechanisms have evolved to restrict the first step in the catalytic cycle of E2 enzymes.
Background:
Pancreatic cancer is a fatal disease associated with resistance to conventional therapies. This study aimed to determine changes in gene expression patterns associated with infection and susceptibility of pancreatic cancer cells to an oncolyticvaccinia virus, GLV-1h153, carrying the human sodium iodide symporter for deep tissue imaging of virotherapy.
Methods:
Replication and susceptibility of pancreatic adenocarcinoma PANC-1 cells to GLV-1h153 was confirmed with replication and cytotoxicity assays. PANC-1 cells were then infected with GLV-1h153 and near-synchronous infection confirmed via flow cytometry of viral-induced green fluorescent protein (GFP) expression. Six and 24 hours after infection, three samples of each time point were harvested, and gene expression patterns assessed using HG-U133A cDNA microarray chips as compared to uninfected control. Differentially expressed genes were identified using Bioconductor LIMMA statistical analysis package. A fold change of 2.0 or above was used as a cutoff, with a P value of 0.01. The gene list was then analyzed using Ingenuity Pathways Analysis software.
Results:
Differential gene analysis revealed a total of 12,412 up- and 11,065 downregulated genes at 6 and 24 hours postinfection with GLV-1h153 as compared to control. At 6 hours postinfection. A total of 139 genes were either up or downregulated >twofold (false discovery rate < 0.05), of which 124 were mapped by Ingenuity Pathway Analysis (IPA). By 24 hours postinfection, a total of 5,698 genes were identified and 5,563 mapped by IPA. Microarray revealed gene expression changes, with gene networks demonstrating downregulation of processes such as cell death, cell cycle, and DNA repair, and upregulation of infection mechanisms (P < 0.01). Six hours after infection, gene changes involved pathways such as HMGB-1, interleukin (IL)-2, IL-6, IL-8, janus kinase/signal tranducer and activator of transcription (JAK/STAT), interferon, and ERK 5 signaling (P < 0.01). By 24 hours, prominent pathways included P53- and Myc-induced apoptotic processes, pancreatic adenocarcinoma signaling, and phosphoinositide 3-kinase/v-akt murine thymoma vial oncogene homolog 1 (PI3/AKT) pathways.
Conclusions:
Our study reveals the ability to assess time-dependent changes in gene expression patterns in pancreatic cancer cells associated with infection and susceptibility to vaccinia viruses. This suggests that molecular assays may be useful to develop safer and more efficacious oncolyticvirotherapies and support the idea that these treatments may target pathways implicated in pancreatic cancer resistance to conventional therapies.
The integrity of its DNA is fundamental for every living cell. However, DNA is constantly threatened by exogenous and endogenous damaging agents that can cause a variety of different DNA lesions. The severe consequences of an accumulation of DNA lesions are reflected in cancerogenesis and aging. Several DNA repair mechanisms ensure the repair of DNA lesions and thus maintain DNA integrity. One of these DNA repair mechanisms is nucleotide excision repair (NER), which is famous for its ability to address a large variety of structurally unrelated DNA lesions. A key component of eukaryotic NER is the transcription factor II H (TFIIH) complex, which is not only essential for DNA repair but also for transcription. The TFIIH complex is composed of ten subunits. How these subunits work together during NER to unwind the DNA around the lesion is, however, not yet fully understood. High-resolution structural data and biochemical insights into the function of every subunit are thus indispensable to understand the functional networks within TFIIH. The importance of an intact TFIIH complex is reflected in the severe consequences of patient mutations in the TFIIH subunits XPB, XPD or p8 leading to the hallmark diseases xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Defects in the NER pathway are further associated with several types of cancer including skin cancer.
The herein described work focused on five TFIIH subunits derived from the thermophilic fungus Chaetomium thermophilum, the p34/p44 pair and the ternary XPB/p52/p8 complex. The interaction between p34 and p44 was characterized based on a high-resolution structure of the p34_vWA/p44_RING minimal complex. Biochemical studies of the p34/p44 interaction led to the disclosure of an additional interaction between the p34 and p44 subunits, which had not been characterized so far. The p34/p44 interaction was shown to be central to TFIIH, which justifies the presence of several redundant interfaces to safeguard the interaction between the two proteins and might explain why so far, no patient mutations in these subunits have been identified. The p52 subunit of TFIIH was known to be crucial to stimulate the ATPase activity of XPB, which is required during NER. This work presents the first entire atomic resolution structural characterization of p52, which was derived of several crystal structures of p52 variants and a p52/p8 variant thereby demonstrating the interaction between p52 and p8. The precise structural model of p52 offered the possibility to investigate interactions with other TFIIH subunits in more detail. The middle domain 2 of p52 and the N-terminal domain of XPB were shown to mediate the main interaction between the two subunits. An analysis of the p52 crystal structures within recently published cryo-electron microscopy structures of TFIIH provides a model of how p52 and p8 stimulate the ATPase activity of XPB, which is essential for NER and transcription. The structural and biochemical findings of this work provide an additional building block towards the uncovering of the architecture and function of this essential transcription factor.
The eukaryotic gene expression requires extensive regulations to enable the homeostasis of the cell and to allow dynamic responses due to external stimuli. Although many regulatory mechanisms involve the transcription as the first step of the gene expression, intensive regulation occurs also in the post-transcriptional mRNA metabolism. Thereby, the particular composition of the mRNPs plays a central role as the components associated with the mRNA form a specific “mRNP code” which determines the fate of the mRNA. Many proteins which are involved in this regulation and the mRNA metabolism are affected in diseases and especially neurological disorders often result from an aberrant mRNP code which leads to changes in the regulation and expression of mRNPs.
The focus of this work was on a trimeric protein complex which is termed TTF complex based on its subunits TDRD3, TOP3β and FMRP. Biochemical investigations revealed that the three components of the TTF complex are nucleo-cytosolic shuttle proteins which localize in the cytoplasm at the steady-state, associate with mRNPs and are presumably connected to the translation. Upon cellular stress conditions, the TTF components concentrate in stress granules. Thus, the TTF complex is part of the mRNP code, however its target RNAs and function are still completely unknown. Since the loss of functional FMRP results in the fragile X syndrome and TOP3β is associated with schizophrenia and intellectual disability, the TTF complex connects these phenotypically related neuro-psychiatric disorders with each other on a molecular level.
Therefore, the aim of this work was to biochemically characterize the TTF complex and to define its function in the mRNA metabolism. In this work, evidence was provided that TDRD3 acts as the central unit of the TTF complex and directly binds to FMRP as well as to TOP3β. Thereby, the interaction of TDRD3 and TOP3β is very stable, whereas FMRP is a dynamic component. Interestingly, the TTF complex is not bound directly to mRNA, but is recruited via the exon junction complex (EJC) to mRNPs. This interaction is mediated by a specific binding motif of TDRD3, the EBM. Upon biochemical and biological investigations, it was possible to identify the interactome of the TTF complex and to define the role in the mRNA metabolism. The data revealed that the TTF complex is mainly associated with “early” mRNPs and is probably involved in the pioneer round of translation. Furthermore, TOP3β was found to bind directly to the ribosome and thus, establishes a connection between the EJC and the translation machinery. A reduction of the TTF components resulted in selective changes in the proteome in cultured cells, whereby individual protein subsets seem to be regulated rather than the global protein expression.
Moreover, the enzymatic analysis of TOP3β indicated that TOP3β is a type IA topoisomerase which can catalytically attack not only DNA but also RNA. This aspect is particularly interesting with regard to the connection between early mRNPs and the translation which has been revealed in this work.
The data obtained in this work suggest that the TTF complex plays a role in regulating the metabolism of an early mRNP subset possibly in the course of the pioneer round of translation. Until now, the link between an RNA topoisomerase and the mRNA metabolism is thereby unique and thus provides a completely new perspective on the steps in the post-transcriptional gene expression and its regulation.
A continuous arms race between the development of novel antibiotics and the evolution of corresponding resistance mechanisms in bacteria has been observed, since antibiotic agents like arsphenamines (e.g. Salvarsan, developed by Paul Ehrlich [1]), sulphonamides (e.g. Prontosil, Gerhard Domagk [2]) and penicillin (Alexander Fleming [3]) were first applied to effectively cure bacterial infections in the early 20th century. The rapid emergence of resistances in contrast to the currently lagging discovery of antibiotics displays a severe threat to human health. Some serious infectious diseases, such as tuberculosis or melioidosis, which were either thought to be an issue only in Third-World countries in case of tuberculosis, or regionally restricted with respect to melioidosis, are now on the rise to expand to other areas. In contrast, methicillin-resistant Staphylococcus aureus (MRSA) is already present in clinical setups all over the world and causes severe infections in immunocompromised patients. Thus, there is an urgent need for new and effective antimicrobial agents, which impair vital functions of the pathogen’s metabolism.
One central metabolic pathway is represented by the bacterial fatty-acid synthesis pathway (FAS II), which is essential for the synthesis of long and branched-chain fatty acids, as well as mycolic acids. These substances play a major role as modulating components of the properties of the most important protective barrier – the cell envelope. The integrity of the bacterial cell wall and the associated membrane(s) is crucial for cell growth and for protection against physical strain, intrusion of antibiotic agents and regulation of uptake of ions and other small molecules. Thus, this central pathway represents a promising target for antibiotic action against pathogens to combat infectious diseases. The last and rate-limiting step is catalysed by the trans-2-enoyl-ACP reductase (ENR) FabI or InhA (in mycobacteria), which has been demonstrated to be a valuable target for drug design and can be addressed, amongst others, by diphenyl ether (DPE) compounds, derived from triclosan (TCL) – the first one of this class which was discovered to bind to ENR enzymes [4, 5].
Based on this scaffold, inhibitors containing different combinations of substituents at crucial positions, as well as a novel type of substituent at position five were investigated regarding their binding behaviour towards the Burkholderia pseudomallei and Mycobacterium tuberculosis ENR enzymes bpFabI and InhA, respectively, by structural, kinetic and in-vivo experiments. Generally, substitution patterns modulate the association and dissociation velocities of the different ENR inhibitors in the context of the two-step slow-onset binding mechanism, which is observed for both enzymes. These alterations in the rapidity of complex formation and decomposition have a crucial impact on the residence time of a compound and hence, on the pharmacokinetic properties of potential drug candidates. For example, the substituents at the 2’-position of the DPE scaffold influence the ground- and transition state stability during the binding process to bpFabI, whereas 4’-substituents primarily alter the transition state [6]. The novel triazole group attached to the 5-position of the scaffold, targeting the hydrophobic part of the substrate-binding pocket in InhA, significantly enhances the energy barrier of the transition state of inhibitor binding [7] and decelerates the association- as well as the dissociation processes. Combinations with different substituents at the 2’-position can enhance or diminish this effect, e.g. by ground-state stabilisation, which will result in an increased residence time of the respective inhibitor on InhA.
Further structural investigations carried out in this work, confirm the proposed binding mode of a customised saFabI inhibitor [8], carrying a pyridone moiety on the DPE scaffold to expand interactions with the protein environment. Structural and preliminary kinetic data confirm the binding of the same inhibitor to InhA in a related fashion. Comparisons with structures of the ENR inhibitor AFN-1252 [9] bound to ENR enzymes from other organisms, addressing a similar region as the pyridone-moiety of the DPE inhibitor, suggest that also the DPE inhibitor bears the potential to display binding to homologues of saFabI and InhA and may be optimised accordingly.
Both of the newly investigated substituents, the pyridone moiety at the 4’-position as well as the 5-triazole substituent, provide a good starting point to modify the DPE scaffold also towards improved kinetic properties against ENR enzymes other than the herein studied and combining both groups on the DPE scaffold may have beneficial effects. The understanding of the underlying binding mechanism is a crucial factor to promote the dedicated design of inhibitors with superior pharmacokinetic characteristics.
A second target for a structure-based drug-design approach is the interaction surface between ENR enzymes and the acyl-carrier protein (ACP), which delivers the growing acyl chain to each distinct enzyme of the dissociated FAS-II system and presumably recognises its respective interaction partner via electrostatic contacts. The interface between saACP and saFabI was investigated using different approaches including crosslinking experiments and the design of fusion constructs connecting the ACP and the FabI subunits via a flexible linker region of varying lengths and compositions. The crosslinking studies confirmed a set of residues to be part of the contact interface of a previously proposed complex model [10] and displayed high crosslinking efficiency of saACP to saFabI when mutated to cysteine residues. However, crystals of the complex obtained from either the single components, or of the fusion constructs usually displayed weak diffraction, which supports the assumption that complex formation is highly transient. To obtain ordered crystals for structural characterisation of the complex it is necessary to trap the complex in a fixed state, e.g. by a high-affinity substrate attached to ACP [11], which abolishes rapid complex dissociation. For this purpose, acyl-coupled long-residence time inhibitors might be a valuable tool to elucidate the detailed architecture of the ACP-FabI interface. This may provide a novel basis for the development of inhibitors that specifically target the FAS-II biosynthesis pathway.
Cryptochrome (CRY) is the primary photoreceptor of Drosophila’s circadian clock. It resets the circadian clock by promoting light-induced degradation of the clock protein Timeless (TIM) in the proteasome. Under constant light, the clock stops because TIM is absent, and the flies become arrhythmic. In addition to TIM degradation, light also induces CRY degradation. This depends on the interaction of CRY with several proteins such as the E3 ubiquitin ligases Jetlag (JET) and Ramshackle (BRWD3). However, CRY can seemingly also be stabilized by interaction with the kinase Shaggy (SGG), the GSK-3 beta fly orthologue. Consequently, flies with SGG overexpression in certain dorsal clock neurons are reported to remain rhythmic under constant light. We were interested in the interaction between CRY, Ramshackle and SGG and started to perform protein interaction studies in S2 cells. To our surprise, we were not able to replicate the results, that SGG overexpression does stabilize CRY, neither in S2 cells nor in the relevant clock neurons. SGG rather does the contrary. Furthermore, flies with SGG overexpression in the dorsal clock neurons became arrhythmic as did wild-type flies. Nevertheless, we could reproduce the published interaction of SGG with TIM, since flies with SGG overexpression in the lateral clock neurons shortened their free-running period. We conclude that SGG does not directly interact with CRY but rather with TIM. Furthermore we could demonstrate, that an unspecific antibody explains the observed stabilization effects on CRY.